These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 742285)

  • 21. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
    J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982.
    Samuelsson B
    Biosci Rep; 1983 Sep; 3(9):791-813. PubMed ID: 6315101
    [No Abstract]   [Full Text] [Related]  

  • 24. Vasoconstrictor response of arterioles of the hamster cheek pouch to norepinephrine, prostaglandin H2, F2 alpha and carbocyclic thromboxane A2, a possible thromboxane A2 analogue.
    Herrmann KS
    Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):180-5. PubMed ID: 6960809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible generation of potent vasocontracting substance from prostaglandin endoperoxide analogs, human platelets mixture.
    Shibata S; Ho WK; Ishida U
    J Pharmacol Exp Ther; 1980 Nov; 215(2):357-62. PubMed ID: 7441499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostaglandins and thromboxanes: "middlemen" modulating platelet function in hemostasis and thrombosis.
    Gerrard JM; White JG
    Prog Hemost Thromb; 1978; 4():87-125. PubMed ID: 213813
    [No Abstract]   [Full Text] [Related]  

  • 28. [Role of prostacyclin and thromboxane A2 in the cardiovascular system].
    Ismailov ShI; Val'dman AV
    Kardiologiia; 1981 Mar; 21(3):111-6. PubMed ID: 7014974
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulation of human lymph contractility by prostaglandins and thromboxane.
    Sinzinger H; Kaliman J; Mannheimer E
    Lymphology; 1984 Jun; 17(2):43-5. PubMed ID: 6381904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of soluble splenic cell guanylate cyclase by prostaglandin endoperoxides and fatty acid hydroperoxides.
    Graff G; Stephenson JH; Glass DB; Haddox MK; Goldberg ND
    J Biol Chem; 1978 Nov; 253(21):7662-76. PubMed ID: 29900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and structure of the platelet aggregation factor thromboxane A2.
    Bhagwat SS; Hamann PR; Still WC; Bunting S; Fitzpatrick FA
    Nature; 1985 Jun 6-12; 315(6019):511-3. PubMed ID: 4000279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bronchial and cardiovascular actions of prostaglandin endoperoxides and an endoperoxide analogue.
    Hedqvist P; Strandberg K; Hamberg M
    Acta Physiol Scand; 1978 Jul; 103(3):299-307. PubMed ID: 726925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Action of the novel selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid on vascular smooth muscle preparations.
    Perzborn E; Seuter F; Fiedler VB; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1522-5. PubMed ID: 2624598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
    Hamberg M; Svensson J; Samuelsson B
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):2994-8. PubMed ID: 1059088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 16-p-fluorophenoxy prostanoid with potent and long-lasting thromboxane-like actions [proceedings].
    Jones RL; Wilson NH
    Br J Pharmacol; 1978 Jun; 63(2):362P. PubMed ID: 667444
    [No Abstract]   [Full Text] [Related]  

  • 38. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
    Smith EF
    Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trimethoquinol selectively antagonises longitudinal muscle contractions of rat isolated gastric fundus to thromboxane B2 and epoxymethano analogues of PGH2 [proceedings].
    Bennett A; Sanger GJ
    Br J Pharmacol; 1979 Jul; 66(3):450P. PubMed ID: 526738
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of prostaglandin H2 on perinatal pulmonary circulation.
    Tod ML; Cassin S; McNamara DB; Kadowitz PJ
    Pediatr Res; 1986 Jun; 20(6):565-9. PubMed ID: 3714368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.